Colliers International Group: Paying A Brokerage Multiple For A Compounder

Colliers (CIGI) is framed as attractively valued at 13.0x forward adjusted earnings versus CBRE at 17.1x, despite lagging peers with a -22.7% total return over the past year versus a 24% peer average. Roughly 70% of earnings are recurring, which supports stability and a potential compounding flywheel. The note is constructive on fundamentals and valuation, but it is analyst commentary rather than a company-specific catalyst.

Analysis

The opportunity is less about multiple expansion in isolation and more about durability of compounding. A business with a high recurring mix tends to de-rate less in slower macro tape, so the current discount to the larger peer can persist until the market is forced to price the cash-flow quality gap rather than headline growth. That makes the setup interesting for a relative-value re-rating rather than a directional beta call.

The second-order beneficiary is likely the broader private-market/outsourced-services ecosystem: if clients continue prioritizing variable-cost, outsourced real estate spend, the firm’s sticky revenue base can feed cross-sell and wallet-share gains that are harder for a pure transactional competitor to defend. The risk for the peer is not just valuation compression; it is that a steadier, more recurring mix can win incremental share in a choppier funding and leasing environment, especially if corporate budgets stay cautious for the next 2-3 quarters.

The main bear case is that cheap can stay cheap if growth inflects slower than expected or if investors keep rewarding the larger platform for liquidity, scale, and index ownership. Near term, any disappointment in transaction activity or earnings cadence can delay the re-rating even if the medium-term thesis remains intact. The market is effectively paying for proof, so the catalyst path matters more than the absolute valuation gap.

Consensus appears to be underestimating how much downside is already embedded after a year of severe underperformance. If the recurring earnings profile holds up in a soft macro backdrop, the stock does not need heroic growth to work; it only needs stabilization and modest multiple normalization over 6-12 months. That creates a favorable asymmetry: limited further derating unless fundamentals break, with meaningful upside if the market reclassifies it as a quality compounder rather than a cyclical services name.

Key Decisions for Investors

• Go long CIGI vs. short CBRE in a market-neutral pair over the next 3-6 months; target a re-rating toward a narrower multiple gap if earnings stability persists, with the pair designed to isolate quality/recurrence over beta.
• Add CIGI on post-earnings weakness rather than pre-event strength; use any 5-8% pullback as an entry point if guidance remains intact, since the setup depends on multiple recovery, not momentum chase.
• Buy 6-12 month CIGI call spreads to express upside with defined risk; this fits a thesis where the stock re-rates gradually rather than gaps higher, improving capital efficiency versus outright long equity.
• If CBRE starts showing slower-than-expected conversion or softer transaction commentary, increase the pair trade rather than adding to single-name CIGI exposure; the relative thesis improves if the market starts pricing dispersion in earnings quality.